Literature DB >> 1576530

Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filaments.

L Baum1, E Masliah, D S Iimoto, L A Hansen, W C Halliday, T Saitoh.   

Abstract

Neurofibrillary tangles (NFT) are pathological cytoskeletal structures composed of paired helical filaments (PHF), and are found in neurons of patients afflicted with many neurodegenerative disorders, including Alzheimer's disease (AD). We previously found that an antiserum against casein kinase II (CK-II) stained NFT intensely in the brain tissue of AD patients. In the current study, we found that the anti-CK-II antiserum stains NFT and neuronal inclusions in many other neurodegenerative diseases as well, including Guam-Parkinson dementia complex, chromosome 18 deletion syndrome, progressive supranuclear palsy, Kufs' disease, and Pick's disease. This antiserum reacted, in crude brain homogenates, with both a doublet of Mr 43,000 and a Mr 27,000 Da protein which could correspond to the alpha, alpha', and beta chains of CK-II. The staining of these bands was adsorbed by preincubating anti-CK-II antiserum with purified CK-II. Preincubation of brain sections with purified CK-II strongly intensified the immunostaining of NFT with anti-CK-II, suggesting that NFT may bind CK-II. In the AD brain homogenates, the particulate CK-II levels are increased whereas the cytosolic levels are decreased without a change in total CK-II levels, consistent with the idea that CK-II binds to the particulate PHF, a major constituent of NFT. In accord with these findings, purified PHF bound CK-II, but purified PHF did not contain CK-II as its component. These results suggest that CK-II might be an extraneously deposited component of NFT. Thus, the altered CK-II compartmentalization might have significant consequences in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576530     DOI: 10.1016/0006-8993(92)90121-o

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Gene expression correlates of neurofibrillary tangles in Alzheimer's disease.

Authors:  Travis Dunckley; Thomas G Beach; Keri E Ramsey; Andrew Grover; Diego Mastroeni; Douglas G Walker; Bonnie J LaFleur; Keith D Coon; Kevin M Brown; Richard Caselli; Walter Kukull; Roger Higdon; Daniel McKeel; John C Morris; Christine Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan
Journal:  Neurobiol Aging       Date:  2005-10-19       Impact factor: 4.673

Review 2.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

Review 3.  Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy.

Authors:  L W Jin; T Saitoh
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

4.  Casein kinase II alteration precedes tau accumulation in tangle formation.

Authors:  E Masliah; D S Iimoto; M Mallory; T Albright; L Hansen; T Saitoh
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

5.  Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.

Authors:  Andrea F N Rosenberger; Riet Hilhorst; Elisabeth Coart; Leandro García Barrado; Faris Naji; Annemieke J M Rozemuller; Wiesje M van der Flier; Philip Scheltens; Jeroen J M Hoozemans; Saskia M van der Vies
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 6.  CK2-An Emerging Target for Neurological and Psychiatric Disorders.

Authors:  Julia Castello; Andre Ragnauth; Eitan Friedman; Heike Rebholz
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-05

7.  Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells.

Authors:  L Ulloa; J Díaz-Nido; J Avila
Journal:  EMBO J       Date:  1993-04       Impact factor: 11.598

8.  Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology.

Authors:  Andrea F N Rosenberger; Tjado H J Morrema; Wouter H Gerritsen; Elise S van Haastert; Hripsime Snkhchyan; Riet Hilhorst; Annemieke J M Rozemuller; Philip Scheltens; Saskia M van der Vies; Jeroen J M Hoozemans
Journal:  J Neuroinflammation       Date:  2016-01-06       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.